PRINCETON, N.J.–(BUSINESS WIRE)– March 18, 2022 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag (nivolumab and relatlimab-rmbw),anew, first-in-class,fixed-dose combination of nivolumab and relatlimab, administered as a single…Original Article
FDA Approves Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Patients with Unresectable or Metastatic Melanoma
